Biomarkers of the Central Nervous System (CNS) aid in the discovery and development of new drugs, as well as decision-making about drug therapy and effectiveness. Furthermore, biomarkers aid in the knowledge of illness mechanisms and the improvement of patient care quality. New technology breakthroughs and their rising application in the diagnosis of neurodegenerative illnesses are two important reasons driving the CNS biomarkers market. Furthermore, increased R&D for new CNS biomarkers as well as successful clinical studies contribute to the growth of the central nervous system biomarkers market.
Changes in government rules and policies, on the other hand, are limiting the growth of the central nervous system biomarkers market, as reimbursements do not cover biomarker-mediated medicines that are not considered standard of care. Despite the fact that biomarkers have a great value for tests, there are some limitations.
Read more @ https://bit.ly/3rSrFG9
